Literature DB >> 10895230

Outbreak of neonatal Klebsiella septicaemia: a review of antimicrobial sensitivities.

J A Akindele1, I O Rotilu.   

Abstract

A 10-week prospective study was undertaken to document the antibiotic susceptibilities of klebsiella organisms which were responsible for an outbreak of septicaemia on the neonatal units of the University College Hospital, Ibadan, Nigeria. The thirty-nine isolates obtained comprised K. pneumoniae, 18 (46.2%), K. aerogenes, 17 (43.6%), K. edwardsii, 3 (7.7%), and K. oxytoca, 1(2.5%). All the strains were sensitive to ciprofloxacin and ofloxacin, but resistant to ampicillin. The percentage of qualitative sensitivities of the klebsiella species to other available drugs were 41% for ceftazidime, 36% for cefotaxime, 31% for ceftriazone, 23% for cefuroxime, 21% for gentamycin, and 15% for kanamycin. Quantitative sensitivities of the three most commonly isolated sub-types to netilmycin were 63%, 36%, and 33%, respectively. A comparison with a previous antibiotic susceptibility study still showed persistent resistance to the available aminoglycosides.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10895230

Source DB:  PubMed          Journal:  Afr J Med Med Sci        ISSN: 0309-3913


  3 in total

Review 1.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

2.  Arthritis, osteomyelitis, septicemia and meningitis caused by Klebsiella in a low-birth-weight newborn: a case report.

Authors:  Ziaaedin Ghorashi; Nariman Nezami; Hamideh Hoseinpour-Feizi; Sona Ghorashi; Jafar Sadegh Tabrizi
Journal:  J Med Case Rep       Date:  2011-06-27

3.  Phenotypic expression and prevalence of ESBL-producing Enterobacteriaceae in samples collected from patients in various wards of Mulago Hospital, Uganda.

Authors:  John N Kateregga; Ronah Kantume; Collins Atuhaire; Musisi Nathan Lubowa; James G Ndukui
Journal:  BMC Pharmacol Toxicol       Date:  2015-06-02       Impact factor: 2.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.